Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. insider trading report: President and CEO Charles Janac, who is also a director and 10% owner of Arteris, reported selling 11,145 shares of common stock on 01/06/2026 at a weighted average price of $16.9032 per share, in transactions executed between $15.86 and $17.65. The sale was made under a Rule 10b5-1 trading plan adopted on March 5, 2025.
After this sale, Janac directly beneficially owned 139,487 Arteris shares. He also had indirect beneficial ownership of 9,469,071 shares held by Bayview Legacy, LLC, where he is the manager and has voting and dispositive power, and 56,252 shares held by the Charles and Lydia Janac Trust, for which he serves as trustee.
Arteris, Inc. Chief Operating Officer Moll Laurent R reported a small insider sale of common stock. On January 6, 2026, the executive sold 1,420 shares at a price of $16.23 per share. After this transaction, Moll Laurent R directly held 250,573 shares of Arteris common stock. The sale was made under a Rule 10b5-1 trading plan that the reporting person adopted on March 12, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.
Form 144 reports a planned sale of 150,000 common shares of the issuer’s stock through Morgan Stanley Smith Barney LLC on or about 01/08/2026, to be traded on NASDAQ. The shares to be sold have an indicated aggregate market value of 2,613,000.00, and the issuer has 43,683,773 shares outstanding.
The seller acquired these 150,000 common shares on 11/05/2013 in a private acquisition from the issuer, paid in cash. The filing also lists sales during the past three months, including 10b5-1 sales for K. Charles Janac and Bayview Legacy, LLC, such as 70,000 shares sold on 12/08/2025 for 1,239,964.00 and 50,000 shares sold on 11/10/2025 for 736,830.00.
Arteris, Inc. director Joachim Kunkel reported receiving 910 shares of common stock as fully vested restricted stock on January 5, 2026. These shares represent retainer fees that he elected to take in stock instead of cash. The shares were acquired at a stated price of $0.00 per share, reflecting their nature as compensation rather than an open-market purchase. After this grant, Kunkel beneficially owned 68,728 shares of Arteris common stock in direct ownership. He also elected to defer the receipt of the shares, indicating that while the award is fully vested, delivery of the stock is postponed under a deferral arrangement.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported option exercises and stock sales in a Form 4. On January 5, 2026, he exercised options for 2,500 shares of common stock at an exercise price of $9.28 per share, increasing his holdings to 64,468 shares directly owned.
On the same day, he sold 2,500 shares at $16.00, and on January 6, 2026 he sold an additional 4,318 shares at a weighted average price of $16.8913, with actual sale prices ranging from $15.86 to $17.62. After these transactions, he directly owned 57,650 shares of Arteris common stock. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on June 5, 2025, and that the options for 2,500 shares vest quarterly over 16 quarters starting April 1, 2025 and expire on February 20, 2035.
Nicholas Hawkins has filed a Form 144 notice to sell 5,836 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $102,596.88 on the NASDAQ market. These shares were acquired on 01/01/2026 as restricted stock units from the issuer. The filing notes that there were 43,683,773 shares outstanding of the same class. Over the past three months, Hawkins has already sold additional common shares, including 4,472 shares for $69,079.43 on 01/02/2026, 721 shares for $12,660.76 on 12/08/2025 under a Rule 10b5-1 sales plan, and 438 shares for $6,493.17 on 12/02/2025.
Arteris, Inc. President and CEO Charles K. Janac, who is also a director and 10% owner, reported sales of company common stock on January 2, 2026. He sold 3,185, 1,618, and 3,020 shares of Arteris common stock at a price of $15.4471 per share, with the filing stating that the shares were sold to satisfy his tax liability arising from the release of restricted stock units. After these transactions, he directly beneficially owned 150,632 shares of common stock. The filing also reports indirect beneficial ownership of 9,469,071 shares through Bayview Legacy, LLC, where he is the manager with voting and dispositive power, and 56,252 shares held by the Charles and Lydia Janac Trust, for which he serves as trustee.
Form 144 shows a planned sale of 11,145 common shares of the issuer’s stock. The shares are to be sold through Morgan Stanley Smith Barney LLC in New York, with an aggregate market value of $180,883.35 and are listed on NASDAQ. The approximate sale date indicated is January 6, 2026.
The 11,145 shares were acquired from the issuer on January 1, 2026 as restricted stock units, with the same date shown for payment and the nature of payment marked as N/A. The filing also lists prior sales over the past three months, including multiple 10b5-1 sales by Bayview Legacy, LLC and additional sales by K. Charles Janac, such as 70,000 common shares sold on December 8, 2025 for gross proceeds of $1,239,964.00.
An affiliate of AIP has filed a Form 144 notice indicating an intent to sell 21,818 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/06/2026. The notice states that shares outstanding were 43,683,773 at the time of the filing. Of the shares to be sold, 4,318 were acquired on 01/01/2026 as restricted stock units from the issuer, and 17,500 were acquired on 01/06/2026 through a cash exercise of stock options.
The filing also lists recent sales by or for Paul Alpern over the prior three months under a Rule 10b5-1 trading plan and directly, including multiple transactions of common stock on dates from 11/03/2025 through 01/05/2026 with individual trade sizes up to 7,500 shares. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Arteris, Inc. is using a shelf registration to potentially offer up to $200,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings.
Within this shelf, the company may issue and sell shares of common stock with an aggregate offering price of up to $75,000,000 through an at-the-market program under an Open Market Sale Agreement with Jefferies, which will receive up to 3.0% of gross proceeds as sales agent.
Arteris is a leading provider of semiconductor System IP, including interconnect Networks-on-Chips used in complex System-on-Chip designs, with growth driven by rising chip complexity and AI applications. Its common stock is listed on the Nasdaq Global Market under the symbol AIP, and the last reported sale price was $19.61 per share on December 10, 2025.